Please login to the form below

Not currently logged in
Email:
Password:

Teva's MS drug disappoints in trial

Teva Pharmaceutical Industries has said its oral MS drug laquinimod has failed to reach its primary endpoint in a phase III trial but the company still plans regulatory submissions in the EU and US

Teva Pharmaceutical Industries has said its oral multiple sclerosis (MS) drug laquinimod has failed to reach its primary endpoint in a phase III trial.

Compared to placebo, the therapy, which is being investigated for use in the treatment of relapsing-remitting multiple sclerosis (RRMS), did not reduce annual relapse rates of the disease.

However, Teva said there were dissimilarities in the baseline magnetic resonance imaging (MRI) characteristics of the study group receiving placebo and the study group receiving laquinimod, affecting the trial's results.

When adjusted, laquinimod demonstrated a significant reduction in relapse rate for the disease, as well as a reduced risk of disability progression and brain volume loss.

Teva said additional analyses of the study data are ongoing, and the company still has plans to submit the drug for approval in both the EU and US.

Professor Yitzhak Peterburg, Teva's group vice-president, Global Branded Products, said: "Teva remains committed to the clinical development of laquinimod and is confident that the drug could provide a unique option for the treatment of multiple sclerosis."

2nd August 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Bedrock Healthcare Communications

Bedrock Healthcare Communications is a privately owned, award winning communications agency that creates and delivers highly effective, insight driven medical...

Latest intelligence

ema1
The European Medicines Agency: PRIME’d for access?
Leela Barham examines the impact of the EMA's PRIME fast track system after two years...
How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...

Infographics